Vanguard Global Advisers
PTCT icon

Vanguard Global Advisers’s PTC Therapeutics PTCT Stock Holding History

Vanguard Global Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Sell
37,185
-487
-1% -$35.2K ﹤0.01% 1008
2026
Q1 		$2.57M Buy
+37,672
New +$2.67M ﹤0.01% 1035

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vanguard Global Advisers's PTCT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its PTC Therapeutics (PTCT) stake by 1.3% in Q2 2026, selling an estimated $35.2K and leaving 37,185 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Vanguard Global Advisers first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 374 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Vanguard Global Advisers held 37,185 shares of PTC Therapeutics worth $3.03M as of Q2 2026.
  • Vanguard Global Advisers sold 487 PTC Therapeutics shares in Q2 2026, an estimated $35.2K.
  • PTC Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1008 holding.
  • Vanguard Global Advisers first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 374 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.